Theranica Reports 91% Precision in AI Migraine Forecasting Study
BRIDGEWATER, N.J. and CAESAREA, Israel — September 23, 2026 Theranica announced peer-reviewed results from a study evaluating its Your...
Migraine
Advertisement
Evommune Reports Phase 2b Setback for EVO756 in Atopic Dermatitis
PALO ALTO, Calif. and NEW YORK — September 8, 2026 Evommune, Inc. announced top-line results from its randomized, double-blind,...
Slate Medicines Doses First Participant in SLTE-1009 Study
RALEIGH, N.C. – August 27, 2026 Slate Medicines Inc. announced that the first participant has been dosed in its...
Ceribell Secures CMS NTAP for Delirium Monitor System
SUNNYVALE, Calif., Aug. 3, 2026 Ceribell, Inc. has secured a significant reimbursement milestone after the U.S. Centers for Medicare...
Supernus Pharmaceuticals and Indivior to Merge in $2.2 Billion CNS Biopharma Deal
ROCKVILLE, Md. & RICHMOND, Va., Aug. 3, 2026 Supernus Pharmaceuticals and Indivior Pharmaceuticals announced they have entered into a...
Advertisements
Evommune Launches Phase 2b Trial of EVO756 for Migraine Prevention
PALO ALTO, Calif., & NEW YORK, July 30, 2026 Evommune announced that the first patient has been dosed in...
HDT Bio Advances HDT-401 into Phase 1 Glioblastoma Trial
MONTREAL, Canada / SEATTLE, Washington, July 12, 2026 HDT Bio Corp. has launched a major Canadian clinical development initiative...
Eisai and Biogen Advance LEQEMBI SC for Alzheimer’s Disease
TOKYO, Japan / CAMBRIDGE, Massachusetts, USA, July 12, 2026 Eisai Co., Ltd. and Biogen Inc. have announced new clinical...
Theranica Expands Nerivio Coverage Across U.S. Insured Population
BRIDGEWATER, New Jersey, USA / CAESAREA, Israel, July 9, 2026 Theranica has announced a major reimbursement milestone for Nerivio®,...
Ipsen Reports Positive Phase III Dysport Migraine Results
PARIS, France, July 9, 2026 Ipsen has announced positive topline Phase III results from its BEOND clinical development program,...
Advertisement
